CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Welcome to Advanz Pharma United Kingdom Medical Information

You are about to enter uk.advanzdigitalhub.com. This is a promotional website pertaining to ADVANZ PHARMA Products. The contents of this website are intended for healthcare professionals in the UK only.

UK/MISC/PM/0024 July 2025
I am a :
home-logo
flag-logo
Country Selector
Selecting a new country will redirect you to our country selector page
Go to Country Selector
  • Home
  • About Us
  • Biosimilars
  • Product Information 
    • Men's Health
      • Tostran®
    • Hepatology
      • Ocaliva®▼
    • Anti-Infective
      • Xydalba (dalbavancin)
      • Exblifep® ▼ (Cefepime/ Enmetazobactam)
  • Prescribing Information 
    • Ciclesonide ADVANZ PHARMA 80 mcg and 160 mcg per metered dose pressurised inhalation, solution
    • Estradiol 10 micrograms vaginal tablets (estradiol hemihydrate)
    • Ibuprofen 10% Gel
    • Nitrofurantoin Mercury Pharma 100 mg prolonged-release capsules
    • OCALIVA®▼ (obeticholic acid)
    • Tostran® (testosterone)20mg/g transdermal gel
    • Xydalba™ (dalbavancin)
    • Zapain 30mg/500mg Tablets (codeine phosphate and paracetamol)
    • EXBLIFEP® ▼ 2 g/0.5 g Cefepime / Enmetazobactam
  • Learning Lab 
    • Webinars
    • Digital Materials
  • Contact Us
Search
Search in all-demand content library:
Homepage /

Xydalba™ (dalbavancin) Product Information

Order by date

Newest Oldest

Xydalba™ (dalbavancin) Indication

2024-08-22


Xydalba™ (dalbavancin) Mechanism of Action

2024-09-05


Xydalba™ (dalbavancin) Pharmacology

2024-09-05


Xydalba™ (dalbavancin) Efficacy

2024-09-05


Xydalba™ (dalbavancin) Dosing & Administration

2024-09-05


Xydalba™ (dalbavancin) Safety & Tolerability

2024-09-05


Xydalba™ (dalbavancin)

2024-09-05

Xydalba® is promoted in the UK by ADVANZ PHARMA Limited. AbbVie Ltd is the Marketing Authorisation Holder.


Xydalba (Dalbavancin) Product Information

2025-05-19


Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/ and also report using the Yellow Card app. The app is available to download from the Apple App Store, or Google Play Store and you can use your Yellow Card website account details on the app to report. Adverse events should also be reported to ADVANZ PHARMA Medical Information via telephone on +44 (0) 208 588 9131 or via e-mail at medicalinformation@advanzpharma.com

VALIDATIONREFERENCE

This promotional website is intended for UK Healthcare Professionals. Any images are models and not real patients.

© 2025 ADVANZ PHARMA. All rights reserved.

Terms & Conditions Privacy & Cookies Notice Contact

Available room

#{title}

#{text}

Confirmation

You are not log in.

You have to be log in to access this feature.

Log in
Meeting.

Click on continue to be redirected to the meeting video room.

Continue

Networking page access list